In the United States, the word legal does not answer every question about sermorelin. A prescribed compounded preparation, a historical approved product, and a research-only powder are different things. The seller, pharmacy, formulation, prescription, and applicable state rules all matter.

A statement that an ingredient can be used in compounding is not a statement that the finished drug is FDA-approved. This guide explains the distinctions to verify with a licensed clinician and pharmacist; it does not certify any particular seller or transaction.

The considered take

Compounding eligibility, prescription access, and FDA approval are separate checks.

What section 503A means

FDA explains that section 503A permits qualifying compounding by a licensed pharmacist or physician when the applicable conditions are met. Bulk-substance eligibility includes routes involving a relevant compendial monograph, a component of an FDA-approved drug, or the 503A bulks list when the other routes do not apply.

It is therefore inaccurate to assume that every ingredient must appear on one particular nominated-substances list. It is equally inaccurate to assume that an ingredient's history authorizes every product, claim, or dispensing arrangement. The pharmacy should explain the current basis for its actual preparation.

Sources: FDA: Bulk drug substances under section 503A · FDA: Compounding questions and answers

Historical GEREF approval has a specific meaning

FDA's 2013 determination stated that certain discontinued GEREF products were not withdrawn for safety or effectiveness reasons. That finding concerns those historical products. It does not grant approval to a current compounded sermorelin vial, tablet, or anti-aging indication.

Read the FDA-approval guide if a sales page uses the history as a broad reassurance. Ask whether the exact finished medicine being proposed is approved, compounded, or something else. Facility registration and pharmacy licensure also do not mean every compounded product is FDA-approved.

Sources: FDA: 2013 GEREF withdrawal determination · FDA: Risks of compounded drugs

A research label does not establish patient access

Products marked for research use are not equivalent to prescriptions dispensed for a patient. A laboratory purity document does not supply a medical assessment, establish human-use suitability, or replace pharmacy oversight.

Avoid treating a purchase button as evidence of lawful clinical care. Identify the prescriber and dispensing pharmacy, confirm their relevant licenses, and make sure the product requires the appropriate prescription. The pharmacy-verification guide provides the practical checks.

Sources: NABP: Buy medication safely · FDA: Compounding questions and answers

State and sports rules are separate again

Telehealth practice depends in part on the patient's location and the clinician's authority to practice there. Shipping availability can also vary. A nationwide-looking website does not prove availability to every patient in every state.

If you compete in sport, a prescription does not automatically satisfy anti-doping rules. Read sports and drug testing. For local access, use the state directory and verify the actual provider's current eligibility rules before paying.

Sources: HHS: Telehealth licensing across state lines · WADA: 2026 Prohibited List

Sources behind this article

Provider pages describe their own services. They are not independent proof of health outcomes. Pricing and availability can change.

  1. FDA: Bulk drug substances under section 503AClinical or regulatory reference · Checked September 20, 2026. Findings apply to the specified molecule, route, and population.
  2. FDA: Compounding questions and answersUS regulator · Compounded medicines differ from FDA-approved generic drugs.
  3. FDA: 2013 GEREF withdrawal determinationFederal Register / FDA · Historical GEREF products were not withdrawn for safety or effectiveness reasons; this does not approve current compounds.
  4. FDA: Risks of compounded drugsUS regulator · Explains lack of FDA approval and the risks of poor-quality compounded preparations.
  5. NABP: Buy medication safelyPharmacy regulator association · Tools for checking online pharmacies and recognizing unsafe sellers.
  6. HHS: Telehealth licensing across state linesUS government guidance · Licensure options depend on the patient location and state rules.
  7. WADA: 2026 Prohibited ListPrimary or authoritative reference · Sermorelin named under S2.2.4; rules are sport- and year-specific.